Described herein is a combination comprising at least one 5-HT4 receptor agonist and at least one phosphodiesterase 4 (PDE4) inhibitor, and methods and uses thereof in the prevention and/or treatment of one or more disorders in which an increased acetylcholine release is desired； for example in the prevention and/or treatment of gastrointestinal disorders, urinary disorders, and/or respiratory disorders.
